Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
106.27 +0.86 (+0.82%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 106.27 unch (unch) 17:20 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
104.31
Day High
106.80
Open 104.31
Previous Close 105.41 105.41
Volume 438,900 438,900
Avg Vol 892,300 892,300
Stochastic %K 89.77% 89.77%
Weighted Alpha +34.19 +34.19
5-Day Change +1.81 (+1.73%) +1.81 (+1.73%)
52-Week Range 64.11 - 139.13 64.11 - 139.13
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,820,907
  • Shares Outstanding, K 48,765
  • Annual Sales, $ 385,690 K
  • Annual Income, $ -287,220 K
  • EBIT $ -274 M
  • EBITDA $ -264 M
  • 60-Month Beta 0.88
  • Price/Sales 13.44
  • Price/Cash Flow N/A
  • Price/Book 89.60

Options Overview Details

View History
  • Implied Volatility 49.00% ( -4.44%)
  • Historical Volatility 47.70%
  • IV Percentile 53%
  • IV Rank 19.94%
  • IV High 117.66% on 12/23/24
  • IV Low 31.91% on 08/23/24
  • Put/Call Vol Ratio 2.39
  • Today's Volume 1,051
  • Volume Avg (30-Day) 1,085
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 23,586
  • Open Int (30-Day) 24,757

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.26
  • Number of Estimates 10
  • High Estimate -0.81
  • Low Estimate -1.63
  • Prior Year -1.09
  • Growth Rate Est. (year over year) -15.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.99 +22.16%
on 04/09/25
Period Open: 120.36
122.97 -13.58%
on 03/28/25
-14.09 (-11.71%)
since 03/25/25
3-Month
86.99 +22.16%
on 04/09/25
Period Open: 103.11
139.13 -23.62%
on 02/21/25
+3.16 (+3.06%)
since 01/24/25
52-Week
64.11 +65.76%
on 06/11/24
Period Open: 71.52
139.13 -23.62%
on 02/21/25
+34.75 (+48.59%)
since 04/25/24

Most Recent Stories

More News
Axsome Therapeutics to Participate in Upcoming Investor Conferences

AXSM : 106.27 (+0.82%)
This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now

RBC flags this biopharma stock as recession-ready, with stellar upside potential hiding in plain sight.

$SPX : 5,525.21 (+0.74%)
$SPX : 5,525.21 (+0.74%)
AXSM : 106.27 (+0.82%)
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

AXSM : 106.27 (+0.82%)
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

AXSM : 106.27 (+0.82%)
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime...

KRYS : 168.06 (-0.63%)
JAZZ : 110.80 (+1.67%)
DVAX : 10.82 (-0.73%)
AXSM : 106.27 (+0.82%)
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and oral orexin 2 receptor agonist, ALKS 2680, in adults with idiopathic hypersomnia...

KRYS : 168.06 (-0.63%)
JAZZ : 110.80 (+1.67%)
ALKS : 27.84 (+0.61%)
AXSM : 106.27 (+0.82%)
Why Shares of Axsome Therapeutics Slumped Today

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand...

NVDA : 111.01 (+4.30%)
AXSM : 106.27 (+0.82%)
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

AXSM : 106.27 (+0.82%)
Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...

MRK : 82.74 (+3.63%)
REGN : 602.64 (+0.48%)
AMGN : 280.84 (+0.36%)
AXSM : 106.27 (+0.82%)
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

AXSM : 106.27 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 109.77
2nd Resistance Point 108.28
1st Resistance Point 107.28
Last Price 106.27
1st Support Level 104.79
2nd Support Level 103.30
3rd Support Level 102.30

See More

52-Week High 139.13
Fibonacci 61.8% 110.47
Last Price 106.27
Fibonacci 50% 101.62
Fibonacci 38.2% 92.77
52-Week Low 64.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective